Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals

Tytuł:
Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals
Autorzy:
Ahmed Mohamed ElGhandour
Essam Mohamed Bayoumy
Wesam Ahmed Ibrahim
Moataz Mohamed Sayed
Ashraf Bekheet Salama
Nahla Mohamed Teama
Mohamed Magdy Salama
Temat:
Vascular endothelial growth factor A
HCV
DAAs
HCC
Surgery
RD1-811
Diseases of the digestive system. Gastroenterology
RC799-869
Źródło:
Egyptian Liver Journal, Vol 11, Iss 1, Pp 1-6 (2021)
Wydawca:
SpringerOpen, 2021.
Rok publikacji:
2021
Kolekcja:
LCC:Surgery
LCC:Diseases of the digestive system. Gastroenterology
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
2090-6226
Relacje:
https://doaj.org/toc/2090-6226
DOI:
10.1186/s43066-020-00073-5
Dostęp URL:
https://doaj.org/article/99ac6f0dbfb64c088c725c7aa1c558d0  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.99ac6f0dbfb64c088c725c7aa1c558d0
Czasopismo naukowe
Abstract Background Hepatocellular carcinoma (HCC) comprises 5.6% of all cancers worldwide representing the sixth most common cancer. It is also the fourth most common cause of cancer-related mortality. Angiogenesis is a main factor in the development of HCC. Vascular endothelial growth factor (VEGF) is considered as the force for physiological and pathological angiogenesis, and overexpression of VEGF is prominent in HCC. We aimed to study the effect of direct-acting antivirals (DAAs) on VEGF considered as the key regulator of angiogenesis in HCC. This cross-sectional study involved fifty patients who were divided into two groups: group I—twenty-five chronic hepatitis C virus (HCV) patients as (cases) subjected to treatment with direct-acting antiviral drugs for 3 months; group II—twenty-five chronic HCV patients developed HCC as (controls). Serum VEGF level was measured in of group I at baseline, at end of treatment, and 3 months after the end of treatment by sofosbuvir 400 mg plus daclatasvir 60 mg for 3 months in the HCV patient group, also VEGF was assessed in group II with HCC. Results Serum VEGF was high in both groups, but it was higher in the HCC group with a statistically significant difference (p < 0.001), also serum VEGF in the HCV group decreased after 3 months at the end of DAA treatment from 209.5 ± 137.6 to 44.1 (31.8–55.3) mg/ml, and all patients who received DAAs achieved sustained virologic response (SVR). Conclusion We found that change in serum VEGF in HCV patients treated with DAAs in this study cannot explain the risk of HCC after treatment by DAAs.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies